Clinical Trial Update: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating almonertinib with cerebral radiation for brain metastases in EGFR-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN